1. 10 Years of belimumab experience: What have we learnt?. (October 2021) Authors: Levy, Roger A; Gonzalez-Rivera, Tania; Khamashta, Munther; Fox, Norma Lynn; Jones-Leone, Angela; Rubin, Bernie; Burriss, Susan W; Gairy, Kerry; Maurik, Andre van; Roth, David A Journal: Lupus Issue: Volume 30:Number 11(2021) Page Start: 1705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN). (14th December 2022) Authors: Anders, Hans-Joachim; Rovin, Brad H; Zhao, Ming-Hui; Malvar, Ana; Hiromura, Keiju; Leone, Angela Jones-; Gonzalez-Rivera, Tania; Gilbride, Jennifer; Madan, Anuradha; Green, Yulia; Roth, David A Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 3 Page Start: A70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Issue 3 (2nd January 2018) Authors: Zhang, Fengchun; Bae, Sang-Cheol; Bass, Damon; Chu, Myron; Egginton, Sally; Gordon, David; Roth, David A; Zheng, Jie; Tanaka, Yoshiya Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 3(2018) Page Start: 355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity. (25th April 2018) Authors: Ramachandran, Sulabha; Parks, Daniel; Kurtinecz, Milena; Roth, David A; Alfonso-Cristancho, Rafael Journal: Journal of comparative effectiveness research Issue: Volume 7:Number 6(2018) Page Start: 581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Issue 2 (5th October 2022) Authors: Petri, Michelle; Landy, Helain; Clowse, Megan E B; Gemzoe, Kim; Khamashta, Munther; Kurtinecz, Milena; Levy, Roger A; Liu, Andrew; Marino, Rebecca; Meizlik, Paige; Pimenta, Jeanne M; Sumner, Kelsey; Tilson, Hugh; Connolly, Mary Beth; Wurst, Keele; Harris, Julia; Quasny, Holly; Juliao, Patricia; R... Journal: Annals of the rheumatic diseases Issue: Volume 82:Issue 2(2023) Page Start: 217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Issue 1 (10th February 2021) Authors: Maslen, Toni; Bruce, Ian N; D'Cruz, David; Ianosev, Mihaela; Bass, Damon L; Wilkinson, Christel; Roth, David A Journal: Lupus science & medicine Issue: Volume 8:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. Issue 2 (2nd July 2021) Authors: Tanaka, Yoshiya; Bae, Sang-Cheol; Bass, Damon; Curtis, Paula; Chu, Myron; DeRose, Kathleen; Ji, Beulah; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A Journal: RMD open Issue: Volume 7:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. (February 2021) Authors: Sheikh, Saira Z; Scheinberg, Morton A; Wei, James Cheng-Chung; Tegzova, Dana; Stohl, William; de Toledo, Ricardo Acayaba; Mucenic, Tamara; Banfi, Mauricio R Abello; Maksimowicz-McKinnon, Kathleen; Abud-Mendoza, Carlos; Navarra, Sandra; Garcia, Mercedes; Garcia-De La Torre, Ignacio; Ros, Josep Ord... Journal: Lancet Issue: Volume 3:Number 2(2021) Page Start: e122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. Issue 1 (15th April 2022) Authors: Zhang, Fengchun; Zheng, Jie; Li, Yang; Wang, Guochun; Wang, Mingjun; Su, Yin; Gu, Jieruo; Li, Xingfu; Bass, Damon; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A Journal: RMD open Issue: Volume 8:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE. Issue 1 (7th February 2022) Authors: Struemper, Herbert; Kurtinecz, Milena; Edwards, Lisa; Freimuth, William W; Roth, David A; Stohl, William Journal: Lupus science & medicine Issue: Volume 9:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗